It is estimated that nearly 50% of prescribed drugs / therapies fail to show adequate clinical benefits. It is also worth highlighting that companion diagnostics (CDX) guided drug development efforts have been estimated to help reduce clinical trial costs by almost 60%. Since the approval of the HercepTest (in 1998) for identifying patients for treatment with trastuzumab, over 50 CDX have been developed for various drugs. Several companies have undertaken initiatives to develop biomarker-based therapeutics for other disease indications, such as infectious diseases, neurological disorders and metabolic disorders.
I have highlighted below some of the most interesting insights from our study. You can also access additional details here.
The adoption of CDX by biolgics contract research organizations has led to marked improvement in clinical trial success rates, resulting in reduced mortality due to drug side effects and more precise treatment-related decision making.
Presently, over 130 CDX tests, designed to enable better treatment related decisions, are either already available in the market, or under development by various companies across the world
Based on validated disease-specific biomarkers, these diagnostic tests are known to utilize a variety of analytical tools and techniques for assessing therapeutic compatibility across diverse disease indications
Several companies in this domain have already established strong brand positions in the global market, and are expected to continue to innovate in terms of improving assay techniques and upgrading analytical paradigms
This field is characterized by a value chain, involving drug and diagnostics developers, along with other important stakeholders, each having a discrete set of priorities and requirements
Increase in partnership activity reflects the growing interest of stakeholders; over 70% of reported deals were focused on oncological disorders, involving both international and indigenous stakeholders
With potential applications across a myriad of disease indications, the companion diagnostics market is expected to witness a double digit growth; the opportunity is likely to be distributed across different regions and techniques
In the long-term, the growth momentum will be driven by the niche tumour hotspots which have been identified as promising biological targets for development of CDX.
To learn more, please click here. For any queries / suggestions, please do not hesitate to contact us at email@example.com. Alternatively, you can also download the SAMPLE REPORT on CDX by Roots Analysis..
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.